CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Marc Ferrante  1     Laurent Peyrin-Biroulet  2     Axel Dignass  3     David T. Rubin  4     Silvio Danese  5     Geert R. D'Haens  6     Kristina Kligys  7     Sofie Berg     Jasmina Kalabic  8     Javier Zambrano     Yafei Zhang     Toshimitsu Fujii  9     Remo Panaccione  10    
1 University Hospitals Leuven, Leuven, Belgium
2 Nancy University Hospital, Vandoeuvre-les-Nancy, France
3 Agaplesion Markus Krankenhaus, Frankfurt/Main, Germany
4 University of Chicago Medicine, Chicago, United States
5 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
6 AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
7 AbbVie Inc., North Chicago, United States
8 AbbVie, Ludwigshafen, Germany
9 Tokyo Medical and Dental University, Tokyo, Japan
10 University of Calgary, Calgary, Canada

Topic
IBD, Nurses, Primary Care

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing